Excellent study @migrantmedic @EbnerMD @tmalouff @wgbreen @TheColonelGray @MayoClinic & @MayoRadOnc colleagues 26 patients 10-15% Amyloidosis is local (98% AL type) ~50% recurrence trach-bronch Dz w/surgery alone If bulky residual consider RT boost

H&N Amyloidosis majority tracheal-bronchial 20Gy/10 most common regimen-min toxicity 66% symptom improve 93% fav response (1/2stable 1/2response) Consider RT for high risk or recurrent Dz https://t.co/IqixIPtd5m

Congrats Dr. Souvik Sankar Das & colleagues Won’t change my practice, I favor SRS even for many brain mets esp w/ much larger Aizer trial results

Randomized Trial 1-3 brain mets SRS/fSRS vs HA-WBRT+SIB Small trial no diff cognitive/QoL outcomes https://t.co/9jTcoE38hf

Congrats @Rrkotecha @MiamiCancerInst colleagues In my practice radiofrequency ablation/vertebral augmentation primarily for at risk lesions (higher SINS score)

Does the addition of radiofrequency ablation/vertebral augmentation to radiotherapy improve pain outcomes for painful spine mets? NO according to this Phase IIR https://t.co/kUrz5IaeFZ

Pertinent Ongoing Trial: NRG CC009 SCLC brain met HA-WBRT vs SRS Excellent report @TLChaunzwaMD @SalmaJabbour1 @Luke_Pike_MD @alissajcooper & @MSKCancerCenter colleagues

Thoughtful review & case report CNS Management Small Cell Lung CA Authors propose middle ground HA-PCI (between extremes of standard PCI & MRI surveillance) based off CC003 https://t.co/yYiJJRR7g1

Greatly enjoyed the focus on benign diseases at ASTRO. Should there be a change in name to reflect this growing practice?

Kudos Dr. Alati @ChargariC & ATTENTION study team SG & RT combo manageable toxicity on this study

Is RT safe w/Sacituzumab govitecan? 56 patients 37 concurrent 26 sequential Sacituzumab Gr2 RN in 1 of 10 SRS Brain Met patients No Gr3+ AE w/concurrent https://t.co/N5fjJkqixf

Kudos @gene_lamanilao @JHGLab @KathrynTringale & UCSD colleagues 20 pCSI & 13 VMAT CSI patients NO diff Tox @ 3mos

Proton CSI vs VMAT CSI for LMD Protons more systemic therapy after CSI 92% vs 46% Protons less Anemia 20% vs 61%, leukopenia 10% vs 46%, lymphopenia 67% vs 88% OS proton CSI 11 mo vs 5 mo (no diff ECOG adjusted) https://t.co/JT3GOiij1m

Kudos to Dr. Mehta @vinaigondi @BrainTumorDoc @DanTrifMD & METIS team for this positive trial @MayoRadOnc

Is there an alternative to HA-WBRT+memantine to decrease risk of new brain mets? Yes, in this randomized trial Tumor Treating Fields prolongs time to intracranial progression w/o affecting QoL or cognitive function https://t.co/K3OKPJHXCm

Kudos Dr. Slater Dr. Shih & colleagues 2% RN QOL stable @ 5 yrs for vast majority (15% had decline) 60 Glioma patients

Phase 2 Proton Therapy Gliomas 54Gy Gr1-2 59.4Gy Gr3 Serial Cognitive Testing Median FU 7 yrs Only 6% minimal cognitive decline https://t.co/A14qvU0E2C

Congrats @DocJarad & DEPART trial collaborators

AEs Radiotherapy for Dupuytren’s Disease Randomized Trial RT well tolerated w/minimal persistent AEs https://t.co/7d69ijm0FT

🚨 PCI in SCLC: Rethinking the standard 🧠 👩‍⚕️ NRG-CC003 (Phase II/III) • HA-PCI = hippocampal-avoidance prophylactic cranial irradiation • ↓ neurocognitive decline 🧩 • Maintained intracranial control 🎯 • No OS difference ⚖️ 📊 Other HA-PCI trials • PREMER 🇪🇸 → less